Nitazoxanide ( DrugBank: Nitazoxanide )

2 diseases

ID	Disease name (Link within this page)	Number of trials
96	Crohn disease	1
97	Ulcerative colitis	1

96. Crohn disease

Clinical trials : 2,400 / Drugs : 1,391 - (DrugBank : 267) / Drug target genes : 170 - Drug target pathways : 215

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00130390 (ClinicalTrials.gov)	August 2005	12/8/2005	Study of Nitazoxanide Tablets in the Treatment of Mild to Moderate Active Crohn's Disease	Multi-center, Randomized, Double-Blind, Placebo-Controlled Trial of Nitazoxanide Tablets in the Treatment of Mild to Moderate Active Crohn's Disease in Adults	Crohn's Disease	Drug: Nitazoxanide;Other: Placebo	Romark Laboratories L.C.	NULL	Terminated	18 Years	N/A	Both	98	Phase 2	United States

Clinical trials : 2,527 / Drugs : 1,465 - (DrugBank : 259) / Drug target genes : 144 - Drug target pathways : 202

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03441893 (ClinicalTrials.gov)	January 1, 2015	8/2/2018	Role of Intestinal Protozoa and Helminths in the Course of Ulcerative Colitis	Role of Intestinal Protozoa and Helminths in the Course of Ulcerative Colitis	Ulcerative Colitis;Ulcerative Colitis Exacerbation;Protozoan Infections;Helminth Infection	Diagnostic Test: parasitological diagnostics (coproscopy);Drug: Nitazoxanide 500Mg Oral Tablet;Drug: Mesalazine 250Mg Tablet and nitazoxanide 500Mg Oral Tablet;Drug: Mesalazine 250Mg	Research Institute of Epidemiology, Microbiology and Infectious Diseases, Uzbekistan	NULL	Active, not recruiting	18 Years	90 Years	All	300	Phase 1/Phase 2	NULL